annual cash & cash equivalents:
$102.69M-$8.21M(-7.40%)Summary
- As of today (May 29, 2025), ARWR annual cash & cash equivalents is $102.69 million, with the most recent change of -$8.21 million (-7.40%) on September 30, 2024.
- During the last 3 years, ARWR annual cash & cash equivalents has fallen by -$81.75 million (-44.32%).
- ARWR annual cash & cash equivalents is now -53.70% below its all-time high of $221.80 million, reached on September 30, 2019.
Performance
ARWR Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$185.71M+$131.82M(+244.61%)Summary
- As of today (May 29, 2025), ARWR quarterly cash & cash equivalents is $185.71 million, with the most recent change of +$131.82 million (+244.61%) on March 31, 2025.
- Over the past year, ARWR quarterly cash & cash equivalents has increased by +$58.01 million (+45.42%).
- ARWR quarterly cash & cash equivalents is now -59.72% below its all-time high of $461.03 million, reached on December 31, 2019.
Performance
ARWR quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ARWR Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.4% | +45.4% |
| 3 y3 years | -44.3% | +114.9% |
| 5 y5 years | -53.7% | -27.6% |
ARWR Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -44.3% | at low | -4.7% | +244.6% |
| 5 y | 5-year | -53.7% | at low | -50.1% | +244.6% |
| alltime | all time | -53.7% | >+9999.0% | -59.7% | >+9999.0% |
ARWR Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $185.71M(+244.6%) |
| Dec 2024 | - | $53.89M(-47.5%) |
| Sep 2024 | $102.69M(-7.4%) | $102.69M(+52.8%) |
| Jun 2024 | - | $67.20M(-47.4%) |
| Mar 2024 | - | $127.70M(+119.4%) |
| Dec 2023 | - | $58.22M(-47.5%) |
| Sep 2023 | $110.89M(+2.7%) | $110.89M(+5.3%) |
| Jun 2023 | - | $105.33M(-22.0%) |
| Mar 2023 | - | $134.96M(-30.8%) |
| Dec 2022 | - | $194.95M(+80.5%) |
| Sep 2022 | $108.00M(-41.4%) | $108.00M(-22.5%) |
| Jun 2022 | - | $139.44M(+61.4%) |
| Mar 2022 | - | $86.41M(-5.7%) |
| Dec 2021 | - | $91.59M(-50.3%) |
| Sep 2021 | $184.43M(+28.5%) | $184.43M(-43.4%) |
| Jun 2021 | - | $325.98M(-12.5%) |
| Mar 2021 | - | $372.38M(+166.1%) |
| Dec 2020 | - | $139.92M(-2.6%) |
| Sep 2020 | $143.58M(-35.3%) | $143.58M(-34.5%) |
| Jun 2020 | - | $219.32M(-14.5%) |
| Mar 2020 | - | $256.65M(-44.3%) |
| Dec 2019 | - | $461.03M(+107.9%) |
| Sep 2019 | $221.80M(+636.1%) | $221.80M(+17.8%) |
| Jun 2019 | - | $188.33M(+16.5%) |
| Mar 2019 | - | $161.64M(-14.8%) |
| Dec 2018 | - | $189.77M(+529.8%) |
| Sep 2018 | $30.13M(+21.3%) | $30.13M(+7.6%) |
| Jun 2018 | - | $28.00M(-59.9%) |
| Mar 2018 | - | $69.81M(+505.4%) |
| Dec 2017 | - | $11.53M(-53.6%) |
| Sep 2017 | $24.84M(-70.9%) | $24.84M(-35.3%) |
| Jun 2017 | - | $38.38M(-37.8%) |
| Mar 2017 | - | $61.72M(-39.6%) |
| Dec 2016 | - | $102.11M(+19.6%) |
| Sep 2016 | $85.37M(+5.1%) | $85.37M(+95.7%) |
| Jun 2016 | - | $43.62M(-13.3%) |
| Mar 2016 | - | $50.30M(-19.1%) |
| Dec 2015 | - | $62.17M(-23.5%) |
| Sep 2015 | $81.21M(-38.7%) | $81.21M(-6.9%) |
| Jun 2015 | - | $87.25M(-9.5%) |
| Mar 2015 | - | $96.45M(-7.3%) |
| Dec 2014 | - | $103.99M(-21.5%) |
| Sep 2014 | $132.51M(+593.3%) | $132.51M(-4.2%) |
| Jun 2014 | - | $138.35M(-3.1%) |
| Mar 2014 | - | $142.85M(+139.2%) |
| Dec 2013 | - | $59.71M(+212.4%) |
| Sep 2013 | $19.11M(+466.0%) | $19.11M(-34.1%) |
| Jun 2013 | - | $29.03M(+776.0%) |
| Mar 2013 | - | $3.31M(+13.1%) |
| Dec 2012 | - | $2.93M(-13.2%) |
| Sep 2012 | $3.38M | $3.38M(+48.0%) |
| Jun 2012 | - | $2.28M(-36.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $3.60M(-46.9%) |
| Dec 2011 | - | $6.77M(-9.8%) |
| Sep 2011 | $7.51M(+9.6%) | $7.51M(+73.9%) |
| Jun 2011 | - | $4.32M(-9.9%) |
| Mar 2011 | - | $4.79M(-12.4%) |
| Dec 2010 | - | $5.47M(-20.2%) |
| Sep 2010 | $6.85M(+238.9%) | $6.85M(-23.8%) |
| Jun 2010 | - | $8.98M(+246.4%) |
| Mar 2010 | - | $2.59M(-31.9%) |
| Dec 2009 | - | $3.81M(+88.6%) |
| Sep 2009 | $2.02M(-80.0%) | $2.02M(+5.8%) |
| Jun 2009 | - | $1.91M(-46.3%) |
| Mar 2009 | - | $3.56M(-53.4%) |
| Dec 2008 | - | $7.64M(-24.3%) |
| Sep 2008 | $10.09M(-58.2%) | $10.09M(-27.0%) |
| Jun 2008 | - | $13.82M(-29.2%) |
| Mar 2008 | - | $19.52M(-23.2%) |
| Dec 2007 | - | $25.42M(+5.4%) |
| Sep 2007 | $24.12M(-13.9%) | $24.12M(+605.0%) |
| Jun 2007 | - | $3.42M(-84.2%) |
| Mar 2007 | - | $21.59M(-23.6%) |
| Dec 2006 | - | $28.27M(+0.9%) |
| Sep 2006 | $28.02M(+24.7%) | $28.02M(+67.9%) |
| Jun 2006 | - | $16.69M(+0.6%) |
| Mar 2006 | - | $16.58M(-13.2%) |
| Dec 2005 | - | $19.11M(-15.0%) |
| Sep 2005 | $22.47M(+162.7%) | $22.47M(-10.6%) |
| Jun 2005 | - | $25.12M(+169.8%) |
| Mar 2005 | - | $9.31M(+37.6%) |
| Dec 2004 | - | $6.77M(-20.9%) |
| Sep 2004 | $8.55M(+531.1%) | $8.55M(-13.1%) |
| Jun 2004 | - | $9.84M(-4.8%) |
| Mar 2004 | - | $10.33M(+623.1%) |
| Dec 2003 | - | $1.43M(+5.4%) |
| Sep 2003 | $1.36M(+7225.9%) | $1.36M(>+9900.0%) |
| Jun 2003 | - | $5000.00(+1150.0%) |
| Mar 2003 | - | $400.00(-90.0%) |
| Dec 2002 | - | $4000.00(-78.4%) |
| Sep 2002 | $18.50K(+6066.7%) | $18.50K(-67.4%) |
| Jun 2002 | - | $56.80K(+1858.6%) |
| Mar 2002 | - | $2900.00(+45.0%) |
| Dec 2001 | - | $2000.00(+566.7%) |
| Sep 2001 | $300.00(-85.0%) | $300.00(-70.0%) |
| Jun 2001 | - | $1000.00(+400.0%) |
| Mar 2001 | - | $200.00(-33.3%) |
| Dec 2000 | - | $300.00(-85.0%) |
| Sep 2000 | $2000.00(+1900.0%) | $2000.00(+300.0%) |
| Jun 2000 | - | $500.00(-37.5%) |
| Mar 2000 | - | $800.00(+700.0%) |
| Dec 1999 | - | $100.00 |
| Sep 1999 | $100.00(-90.0%) | - |
| Sep 1998 | $1000.00(-16.7%) | - |
| Sep 1997 | $1200.00 | - |
FAQ
- What is Arrowhead Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
What is Arrowhead Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of ARWR is $102.69M
What is the all time high annual cash & cash equivalents for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual cash & cash equivalents is $221.80M
What is Arrowhead Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, ARWR annual cash & cash equivalents has changed by -$8.21M (-7.40%)
What is Arrowhead Pharmaceuticals quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ARWR is $185.71M
What is the all time high quarterly cash & cash equivalents for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly cash & cash equivalents is $461.03M
What is Arrowhead Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
Over the past year, ARWR quarterly cash & cash equivalents has changed by +$58.01M (+45.42%)